에 대한 최신 뉴스 Exelixis (NASDAQ:EXEL) 주식

Exelixis

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

EXEL

GRMN

MBLY

PAYC

RBLX

RDDT

SNAP

TEAM

TWLO

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 레딧(NYSE:RDDT)의 주가는 회사가 3분기 실적을 보고하고 예상보다 높은 4분기 매출 지침을 발표한 후 38.86% 상승했으며 많은 분석가들이 주가 예측을 상향했다.

레딧, 로블록스 및 가민은 지난주 최고 성과를 보여준 10개 대형주 중 일부 (10월 28일-11월 1일)

Exelixis Inc

EXELA TECHNOLOGIES INC by Exela Technologies, Inc.

Exela Technologies Inc

EXELA TECHS INC 6% SER B by Exela Technologies, Inc.

Exelon Corp

BMO Capital analyst Etzer Darout downgrades Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) from Outperform to Market Perform and raises the price target from $36 to $40.

News

Downgrades

Price Target

Analyst Ratings

BMO Capital Downgrades Exelixis to Market Perform, Raises Price Target to $40

Exelixis's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NYSE">EXEL</a>) short percent of float has risen 5.91% since its last report. The company recently reported that it has 8.36 million shares sold short, which is 3.94% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.73 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Exelixis Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734549316_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Exelixis has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Exelixis's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Exelixis's peer group average for short interest as a percentage of float is 4.93%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Exelixis's Recent Short Interest

WIIM

Exelixis shares are trading lower after B of A Securities downgraded the stock from Buy to Neutral.

Across the recent three months, 19 analysts have shared their insights on Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">10</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Exelixis, revealing an average target of $32.53, a high estimate of $39.00, and a low estimate of $27.00. This upward trend is evident, with the current average reflecting a 10.27% increase from the previous average price target of $29.50.
<img src="https://www.benzinga.com/files/images/story/2024/1734440441_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Exelixis. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$33.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$36.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$38.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$36.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Yaron Werber</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$30.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$34.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$34.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Jefferson Harralson</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Silvan Tuerkcan</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$30.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Exelixis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Exelixis compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Exelixis's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Exelixis's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EXEL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Exelixis analyst ratings.</a>
<h2>All You Need to Know About Exelixis</h2>
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
<h3>Understanding the Numbers: Exelixis's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Exelixis displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 14.33%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Exelixis's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 21.87% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Exelixis's ROE stands out, surpassing industry averages. With an impressive ROE of 5.37%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.12%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.09, Exelixis adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Exelixis Through The Eyes Of 19 Analysts

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>JMP Securities analyst Mitch Germain downgraded Agree Realty Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>) from Market Outperform to Market Perform. Agree Realty shares closed at $74.05 on Monday. See how other analysts view this stock.</li>
<li>Morgan Stanley analyst Meta Marshall downgraded the rating for CommScope Holding Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) from Equal-Weight to Underweight and maintained the price target of $5. CommScope shares closed at $5.80 on Monday. <a href="https://www.benzinga.com/quote/KR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst James Heaney downgraded Match Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) from Buy to Hold and lowered the price target from $40 to $32. Match Group shares closed at $32.36 on Monday. <a href="https://www.benzinga.com/quote/KR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Jason Gerberry downgraded the rating for Exelixis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) from Buy to Neutral but raised the price target from $35 to $39. Exelixis shares closed at $36.07 on Monday. See how other analysts view this stock.</li>
<li>Goldman Sachs analyst Salveen Richter downgraded Apellis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) from Buy to Neutral and announced a $36 price target. Apellis Pharmaceuticals shares closed at $33.66 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying MTCH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="594" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17075728/image-147-1024x594.png" alt="" class="wp-image-695695" style="width:640px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17075728/image-147-1024x594.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17075728/image-147-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17075728/image-147-768x445.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17075728/image-147.png 1112w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42507875/how-to-earn-500-a-month-from-worthington-enterprises-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Worthington Enterprises Stock Ahead Of Q2 Earnings</a></li>
</ul>

Pre-Market Outlook

Markets

APLS

COMM

MTCH

This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

B of A Securities analyst Jason Gerberry downgrades Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) from Buy to Neutral and raises the price target from $35 to $39.

B of A Securities Downgrades Exelixis to Neutral, Raises Price Target to $39

The Institute for Clinical and Economic Review (ICER) has identified five prescription drugs whose price increases in 2023 lacked sufficient clinical evidence to justify the hikes.
Gilead Sciences Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) Biktarvy, Johnson &amp; Johnson's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Darzalex, Novartis AG's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Entresto, Exelixis Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) Cabometyx, and Pfizer Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Xeljanz are among the five drugs flagged for unsupported price increases.
These five drugs' unsupported net price increases <a target="_blank" href="https://icer.org/news-insights/press-releases/icer-announces-most-significant-drug-price-hikes-unsupported-by-new-clinical-evidence-in-us/" rel="noreferrer noopener">produced</a> $815 million in incremental added costs to U.S. payers in 2023. These price increases contributed significantly to the overall spending surge.
ICER's analysis <a target="_blank" href="https://icer.org/wp-content/uploads/2024/12/UPI_2024_Report_121224.pdf" rel="noreferrer noopener">revealed</a> that the other five drugs on the list did demonstrate new clinical evidence to justify their increased costs.
Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda, AstraZeneca Plc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Imfinizi and Tagrisso, Bristol Myers Squibb &amp; Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo, and Amgen Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Prolia
The findings are part of ICER's latest Unsupported Price Increases (UPI) report, which examines the top 10 drugs with significant net price increases in the past year.
ICER's Vice President of Research, Dr. Foluso Agboola, highlighted the impact of these price hikes, noting they exceed inflation rates and strain the healthcare system.
The ICER report highlighted that Gilead's Biktarvy saw its wholesale acquisition cost increase by 5.9%, with its hike costing U.S. payers $359 million in additional drug spending.
According to the ICER report, the Darzalex price before discounts increased by 7.6%, compared to 6.2% for Entresto, 7.5% for Cabometyx, and 6% for Xeljanz.
Those price increases added an additional $190 million, $108 million, $86 million, and $72 million to 2023 U.S. drug spending, respectively.
Methodology Behind ICER's Findings
<ul>
<li>ICER's evaluation followed a detailed protocol introduced in April 2024. The organization assessed drugs meeting criteria such as ranking among the top 250 by U.S. sales revenue and exceeding consumer price index growth plus 2% in their Wholesale Acquisition Cost.</li>
<li>The analysis focused on distinguishing price increases driven by value from those unrelated to new clinical evidence.</li>
<li>Manufacturers provided input, and ICER reviewed published studies for evidence of additional health benefits.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42468724/warner-bros-discovery-restructures-with-focus-on-streaming-and-tv-divisions-stock-shoots-up" target="_blank" rel="noreferrer noopener">Warner Bros. Discovery Stock Spikes As Board OKs Restructuring Plan</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Biotech

Health Care

Media

General

AMGN

GILD

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report

The Alliance For Clinical Trials In Oncology Independent Data And Safety Monitoring Board Unanimously Recommended That Enrollment In Cabinet Trial Be Stopped And Randomized Patients Be Unblinded To Therapy With The Allowance For Crossover From Placebo To Cabozantinib Due To The Substantial Improvement In Progression-free Survival (Pfs) Observed At This Interim Analysis.

Events

Exelixis Provides Regulatory Update Related To Supplemental New Drug Application For Cabozantinib; Alliance For Clinical Trials In Oncology Independent Data And Safety Monitoring Board Recommends Trial Enrollment To Be Stopped

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) shares jumped 38.86% after the company reported third-quarter results and issued&nbsp;Q4&nbsp;revenue&nbsp;guidance&nbsp;above estimates, and many <a href="https://www.benzinga.com//node/41631795" target="_blank" rel="noreferrer noopener">analysts raised the price forecast</a>.</li>
<li>Paycom Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>) stock escalated 27.95% after the company reported third-quarter results and <a href="https://www.benzinga.com/quote/payc/analyst-ratings" target="_blank" rel="noreferrer noopener">analysts boosted the price forecast</a>.</li>
<li>Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) gained 22.89% last week after the <a href="https://www.benzinga.com//node/41653083" target="_blank" rel="noreferrer noopener">company reported Q3 earnings</a> and sales that beat analyst estimates. Many analysts revised their <a href="https://www.benzinga.com/quote/mbly/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
<li>Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) gained 22.43% after reporting better-than-expected Q3 earnings and raising its FY24 sales outlook. Many <a href="https://www.benzinga.com/quote/EXEL/analyst-ratings" target="_blank" rel="noreferrer noopener">analysts also raised their price forecasts for</a> the stock.</li>
<li>Garmin Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>)&nbsp;shares surged 22.11% after the company reported&nbsp;Q3 financial results <a href="https://www.benzinga.com//node/41625504" target="_blank" rel="noreferrer noopener">and raised its annual&nbsp;outlook</a>.</li>
<li>Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) shares increased 22.07% after the company reported better-than-expected&nbsp;third-quarter results and a year-over-year increase in daily <a href="https://www.benzinga.com//node/41654520" target="_blank" rel="noreferrer noopener">active users and hours engaged</a>. Many analysts upped the <a href="https://www.benzinga.com/quote/rblx/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
<li>Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) stock increased 20.39% after the company reported better-than-<a href="https://www.benzinga.com//node/41639676" target="_blank" rel="noreferrer noopener">expected&nbsp;financial results</a>. Several analysts boosted the <a href="https://www.benzinga.com/quote/twlo/analyst-ratings" target="_blank" rel="noreferrer noopener">stock&#8217;s price forecast</a>.</li>
<li>Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) shares rose 19.90% after the company reported quarterly results and several analysts revised the <a href="https://www.benzinga.com//node/41633681" target="_blank" rel="noreferrer noopener">stock&#8217;s price forecast</a>.</li>
<li>Waters Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) shares gained 19.31% last week. The company reported better-than-expected Q3 earnings and raised its annual outlook.</li>
<li>Atlassian Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) climbed 18.87% last week on Q1 earnings and a strong Q2 outlook. The company&#8217;s board approved a new $1.5 billion share repurchase program, and many <a href="https://www.benzinga.com/quote/team/analyst-ratings" target="_blank" rel="noreferrer noopener">analysts boosted the stock&#8217;s price forecast</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41702898/super-micro-computer-li-auto-and-estee-lauder-are-among-top-10-large-cap-losers-last-week-oct-28-n">Super Micro Computer, Li Auto And Estee Lauder Are Among Top 10 Large Cap Losers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?</a></li>
</ul>
Image via Shutterstock

Large Cap

Movers

Reddit, Roblox And Garmin Are Among Top 10 Large Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio?

Guggenheim analyst Michael Schmidt maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Buy and raises the price target from $32 to $33.

Guggenheim Maintains Buy on Exelixis, Raises Price Target to $33

Stephens &amp; Co. analyst Sudan Loganathan maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Equal-Weight and raises the price target from $23 to $29.

Stephens & Co. Maintains Equal-Weight on Exelixis, Raises Price Target to $29

Piper Sandler analyst Joseph Catanzaro maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Overweight and raises the price target from $33 to $36.

Piper Sandler Maintains Overweight on Exelixis, Raises Price Target to $36

RBC Capital analyst Gregory Renza reiterates Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Outperform and maintains $34 price target.

Reiteration

RBC Capital Reiterates Outperform on Exelixis, Maintains $34 Price Target

Truist Securities analyst Asthika Goonewardene maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Buy and raises the price target from $33 to $38.

Truist Securities Maintains Buy on Exelixis, Raises Price Target to $38

U.S. stocks were higher, with the Dow Jones index gaining around 50 points on Tuesday.
Shares of Snap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) gained 13.5% to $12.38 following better-than-expected <a href="https://www.benzinga.com/news/earnings/24/10/41627569/snap-stock-is-surging-today-whats-going-on">quarterly financial results.</a>
Snap reported third-quarter revenue of $1.373 billion, beating the consensus estimate of $1.358 billion, according to Benzinga Pro. The social media company reported adjusted earnings of 8 cents per share, beating analyst estimates of 5 cents per share.
Snap shares jumped 13.5% to $12.38 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) shares jumped 41.3% to $115.48 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter revenue guidance above estimates.</li>
<li>Omnicell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) gained 37% to $54.99 after the company reported better-than-expected third-quarter financial results and raised its FY24 guidance above estimates.</li>
<li>Unisys Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UIS#NYSE">UIS</a>) surged 30.7% to $7.03 after the company reported better-than-expected third-quarter sales results and raised its FY24 non-GAAP operating profit margin guidance.</li>
<li>ASP Isotopes Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPI#NASDAQ">ASPI</a>) rose 30.7% to $7.53 after the company announced that it has entered into a term sheet with TerraPower for the construction of a HALEU production facility.</li>
<li>NerdWallet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRDS#NASDAQ">NRDS</a>) gained 27.3% to $14.41 after the company reported better-than-expected quarterly revenue results.</li>
<li>AtriCure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) surged 23% to $36.21 after the company reported better-than-expected third-quarter financial results and issued FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on the stock and raised its price target from $34 to $40.</li>
<li>Garmin Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NASDAQ">GRMN</a>) gained 22.9% to $204.48 after the company reported better-than-expected third-quarter financial results and raised annual outlook.</li>
<li>Exelixis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) surged 14.6% to $32.92 after the company reported better-than-expected quarterly financial results and raised its FY24 sales guidance above estimates.</li>
<li>The Cheesecake Factory Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>) gained 13.6% to $48.69 after the company reported better-than-expected quarterly adjusted EPS results. Also, multiple firms raised their respective price targets on the stock.</li>
<li>Adtalem Global Education Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATGE#NASDAQ">ATGE</a>) rose 12.7% to $84.53 following first-quarter results.</li>
<li>FMC Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) gained 11.5% to $67.12 following better-than-expected quarterly earnings.</li>
<li>OneMain Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMF#NYSE">OMF</a>) rose 10.8% to $52.63 following strong quarterly earnings.</li>
<li>Smurfit Westrock Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SW#NYSE">SW</a>) gained 10.4% to $49.38 following third-quarter results.</li>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) surged 6.2% to $129.21.</li>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) gained 5.3% to $180.25 following better-than-expected third-quarter earnings.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41623120/jim-cramer-says-buy-crowdstrike-stock-calls-this-aerospace-manufacturer-is-a-high-specul">Jim Cramer Says Buy CrowdStrike Stock, Calls This Aerospace Manufacturer A &#8216;High Speculative&#8217; Stock</a></li>
</ul>

Intraday Update

ASPI

Adtalem Global Education Inc. Common Stock

ATGE

ATRC

CAKE

DELL

GOOG

NRDS

OMCL

Snap Posts Upbeat Earnings, Joins Unisys, AtriCure, Garmin And Other Big Stocks Moving Higher On Wednesday

Wells Fargo analyst Derek Archila maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Overweight and raises the price target from $32 to $36.

Wells Fargo Maintains Overweight on Exelixis, Raises Price Target to $36

BMO Capital analyst Etzer Darout maintains Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) with a Outperform and raises the price target from $29 to $36.

BMO Capital Maintains Outperform on Exelixis, Raises Price Target to $36

Exelixis shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 sales guidance above estimates.

Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) raises FY2024 sales outlook from $1.98 billion-2.08 billion to $2.15 billion-2.20 billion.

Guidance

Exelixis Raises FY2024 Sales Guidance from $1.98B-2.08B to $2.15B-2.20B (Est $2.050B)

Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $0.35 by 34.29 percent. The company reported quarterly sales of $539.542 million which beat the analyst consensus estimate of $490.020 million by 10.11 percent. This is a 14.33 percent increase over sales of $471.920 million the same period last year.

Earnings

Earnings Beats

Exelixis Q3 2024 Adj. EPS $0.47 Beats $0.35 Estimate, Sales $539.542M Beat $490.020M Estimate

Here are a variety of lesser-known charts from my "Recents" watch list. Quite a few of them look like good bullish plays.

Ten Young Ones

Nine Young Ones

Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating on November 29. Andrew Berens has gi...

Exelixis's Cabozantinib Studies Face Uncertainty and Safety Concerns Leading to Hold Rating

Buy The Post-Election Healthcare Dip With These Stocks

In the expanding oncology market, Exelixis (EXEL) is gaining attention with its strong pipeline and impressive stock performance. With a clear focus on cancer treatment innovation and a growing market presence, is the company set to lead the future of cancer care and treatment? Read more… Exelixis, Inc. (<a href="https://stocknews.com/stock/EXEL/">EXEL</a>) is quickly establishing itself as a major force in the rapidly evolving cancer treatment landscape. Reporting exceptional results for its fiscal third quarter, the company has not only exceeded analyst expectations but is also driving forward with a strong portfolio of innovative therapies.
At the heart of EXEL's success is its impressive pipeline of emerging cancer therapies. The company's flagship product, CABOMETYX&#xAE;, continues to make waves alongside promising treatments like Zanzalintinib, XB010, and XL495. With many of these therapies still in trial phases or awaiting FDA approvals, EXEL is relentlessly working to create better treatment options.
EXEL's achievements are clearly reflected in its stock performance, which has been nothing short of remarkable. In the last three months, the stock surged 31.3%, while over the past year, it rose by an impressive 54.1%, closing the last trading session at $36.07.
So, let us dive into the factors that could shape EXEL's performance in the near future.
Recent Developments
On October 14, EXEL <a href="https://ir.exelixis.com/news-releases/news-release-details/exelixis-and-merck-sign-clinical-development-collaboration">announced a collaboration</a> with Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>) to evaluate the combination of EXEL's zanzalintinib with MRK's KEYTRUDA&#xAE; for the treatment of patients with head and neck squamous cell carcinoma and with renal cell carcinoma. The collaboration has the potential to elevate EXEL's already impressive cancer treatment pipeline.
Earlier this year, on August 6, EXEL caught the attention of the medical community with the <a href="https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-us-food-and-drug-administration-fda-accepted">FDA's acceptance of cabozantinib</a> for the treatment of adults with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.
The acceptance gives the company a powerful tool in the fight against neuroendocrine tumors, one of the more complex and challenging cancer types. This step also strengthens EXEL's position in the oncology market, with more treatment options to offer.
Sound Historical Growth
Over the past three years, EXEL has demonstrated consistent growth across key financial metrics. Its revenue grew at a CAGR of 18.4%, while EBITDA rose faster at 45%. Operational income (EBIT) and total assets expanded at CAGRs of 46.3% and 6.5%, respectively.
Moreover, net income surged at a CAGR of 41.7%, and EPS climbed even higher at 44.8%, showcasing robust profitability.
Strong Financials
For the fiscal 2024 third quarter that ended September 30, EXEL's total revenues increased 14.3% year-over-year to $539.54 million. Its income from operations came in at $136.08 million, compared to a loss from operations of $17.58 million in the previous year's quarter.
Additionally, non-GAAP net income and non-GAAP net income per share rose 322.6% and 370% from the prior year's quarter to $135.66 million and $0.47, respectively.
Favorable Analyst Estimates
Analysts predict EXEL's revenue and EPS for the fiscal fourth quarter ending December 2024 to increase 17.1% and 42.4% year-over-year to $561.61 million and $0.38, respectively. In addition, the company exceeded the consensus revenue and EPS estimates in three of the four trailing quarters.
For the full fiscal year 2024, ending December 2024, EXEL's revenue and EPS are expected to rise 18.1% and 162.6% from the previous year, reaching $2.16 billion and $1.71, respectively.
Discounted Valuation
EXEL is currently trading at a forward P/E of 21.13x, which is 28% lower than the industry average of 29.33x. Moreover, the stock's forward <a href="https://www.investopedia.com/terms/e/ebit-ev-multiple.asp">EV/EBIT multiple</a> stands at 15.89, 4% lower than the industry average of 16.55x. This indicates that EXEL is undervalued compared to the broader market, offering potential upside for investors.
Robust Profitability
EXEL's trailing-12-month gross profit margin of 96.25% is 65% higher than the industry average of 58.35%. Its trailing-12-month EBITDA margin stands at 30.55%, 415.7% higher than the industry average of 5.92%.
Additionally, EXEL's trailing-12-month levered FCF margin of 20.72% outperforms the industry average of 2% by 933.5%. Moreover, the company boasts a trailing-12-month asset turnover ratio of 0.70x, which is 69.6% above the sector average of 0.41x.
POWR Ratings Reflects Optimism
EXEL's strong fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of A, which equates to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by taking into account 118 different factors, with each factor weighted to an optimal degree.
EXEL earns an A grade for Value, driven by its discounted valuation metrics relative to the industry average. It also holds an A for Quality, supported by profitability measures that exceed industry benchmarks. Additionally, EXEL holds a B grade for Sentiment, reflecting the positive outlook from analyst estimates.
Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, the stock is ranked #5 out of 334 stocks. Beyond what is stated above, we have also given EXEL grades for Momentum, Growth, and Stability. Get all EXEL ratings <a href="https://stocknews.com/stock/EXEL/">here</a>.
Bottom Line
EXEL is on the verge of significant success as more and more of the drugs in its pipeline are gaining approval from the FDA and other global regulatory bodies. In addition to its promising pipeline, the company boasts a strong portfolio of cancer therapies that are already making a mark in the market.
With these treatments gaining traction, the company is exceptionally well-positioned to benefit from the rapid growth of emerging cancer therapies. What sets EXEL apart is its combination of high profitability, strong financials, and a valuation that is currently lower than the industry average.
This unique positioning has garnered attention from analysts, who see great potential for the company in the coming years. Thus, now might be the ideal time to consider adding EXEL to an investment portfolio.
How Does Exelixis, Inc. (EXEL) Stack Up Against Its Peers?
Although EXEL's near-term outlook appears sound, it may be worthwhile to explore its industry peers, who also exhibit strong POWR Ratings. So, consider these A (Strong Buy) stocks from the Biotech industry:
Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>)
Genmab A/S (<a href="https://stocknews.com/stock/GMAB/">GMAB</a>)
Jazz Pharmaceuticals plc (<a href="https://stocknews.com/stock/JAZZ/">JAZZ</a>)
To explore more A or B-rated Biotech stocks, <a href="https://stocknews.com/category/biotech/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>
<hr />
EXEL shares were unchanged in premarket trading Tuesday. Year-to-date, EXEL has gained 50.35%, versus a 28.87% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aanchal Sugandh</h2> <img src='https:/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg' style="float:left; padding:5px;width:125px;">Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program.

She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns.<a href="https://stocknews.com/authors/?author=aanchal-sugandh">More...</a>The post <a href=https://stocknews.com/news/exel-gild-gmab-jazz-mrk-is-exelixis-positioned-to-capitalize-on-emerging-cancer-therapies/>Is Exelixis Positioned to Capitalize on Emerging Cancer Therapies?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Is Exelixis Positioned to Capitalize on Emerging Cancer Therapies?

Sairopa has achieved a milestone event in its exclusive clinical development and option agreement with Exelixis (EXEL) involving ADU-1805, an anti-...

Exelixis partner Sairopa provides milestones update

Exelixis cut to neutral from buy by BofA

BMO Capital downgraded Exelixis (EXEL) to Market Perform from Outperform with a price target of $40, up from $36. The "main driver of our thesis ha...

Exelixis downgraded to Market Perform from Outperform at BMO Capital

Exelixis downgraded to market perform by BMO Capital

CLOV

COMP

GAMB

GMAB

GRAB

HSAI

JAZZ

TOST

Press Releases

Exelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine

Small Cap

ONCOLOGY COMMERCIALIZATION LEADER P.J. HALEY TO JOIN NETRAMARK BOARD OF DIRECTORS

Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma

Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories

Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December

Sairopa reports research milestones achieved in partnership with Exelixis, totalling $35 Million from consecutive clinical milestone payments in 2024

AINMF

CSE:AIAI

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BeiGene, Ltd. - American Depositary Shares

BeiGene

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Gilead Sciences

Genmab

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

Vaxcyte

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

BMO Capital

B of A Securities

Guggenheim

Stephens & Co.

Piper Sandler

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?



1. 레딧(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>, NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>)의 주가는 회사가 3분기 실적을 보고하고 예상보다 높은 4분기 매출 지침을 발표한 후 38.86% 상승했으며 많은 분석가들이 <a href="https://kr.benzinga.com/news/usa/stocks/%EB%A0%88%EB%94%A7%EC%9D%98-%EC%A3%BC%EC%8B%9D%EC%9D%B4-%EA%B0%95%EB%A0%A5%ED%95%9C-3%EB%B6%84%EA%B8%B0-%EC%8B%A4%EC%A0%81%EA%B3%BC-4%EB%B6%84%EA%B8%B0-%EC%A0%84%EB%A7%9D%EC%9C%BC%EB%A1%9C-%EC%8B%9C/" target="_blank" rel="noreferrer noopener">주가 예측</a>을 상향했다.



2. 페이컴 소프트웨어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>)의 주가는 회사가 3분기 실적을 보고하고 분석가들이 <a href="https://www.benzinga.com/quote/payc/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 예측</a>을 높인 후 27.95% 상승했다.



3. 모빌아이 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>)의 주가는 회사가 분석가 예상치를 뛰어넘는 <a href="https://www.benzinga.com//node/41653083" target="_blank" rel="noreferrer noopener">3분기 이익과 매출</a>을 보고한 후 지난주에 22.89% 상승했다. 많은 분석가들이 주식 <a href="https://www.benzinga.com/quote/mbly/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 예측</a>을 수정했다.



4. 엑셀리시스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>)의 주식은 예상보다 나은 3분기 실적을 보고하고 FY24 매출 전망을 상향 조정한 후 22.43% 상승했다. 많은 분석가들도 해당 주식에 대한 <a href="https://www.benzinga.com/quote/EXEL/analyst-ratings" target="_blank" rel="noreferrer noopener">가격 예측</a>을 높였다.



5. 가민(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>)의 주식은 회사가 3분기 재무 결과를 보고하고 <a href="https://www.benzinga.com//node/41625504" target="_blank" rel="noreferrer noopener">연간 전망을 상향</a> 조정한 후 주가는 22.11% 급등했다.



6. 로블록스 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>, NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>)의 주식은 회사가 예상보다 나은 3분기 실적을 보고하고 일일 <a href="https://www.benzinga.com//node/41654520" target="_blank" rel="noreferrer noopener">활성 사용자 및 참여 시간</a>이 전년 대비 증가한 후 주가는 22.07% 증가했다. 많은 분석가들이 <a href="https://www.benzinga.com/quote/rblx/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 예측</a>을 높였다.



7. 트윌리오(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>, NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>)의 주식은 회사가 예상보다 나은 <a href="https://www.benzinga.com//node/41639676" target="_blank" rel="noreferrer noopener">재무 결과</a>를 보고한 후 주가는 20.39% 증가했다. 몇몇 분석가는 <a href="https://www.benzinga.com/quote/twlo/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 예측</a>을 상향 조정했다.



8. 스냅(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>)의 주식은 회사가 분기별 실적을 보고하고 여러 분석가가 <a href="https://www.benzinga.com//node/41633681" target="_blank" rel="noreferrer noopener">주가 예측</a>을 수정한 후 주가는 19.90% 상승했다.



9. 워터스 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>)의 주식은 지난주 주가는 19.31% 상승했다. 회사는 예상보다 나은 3분기 실적을 발표하고 연간 전망을 상향 조정했다.



10. 아틀라시안 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>)의 주식은 지난주 1분기 실적과 2분기 전망이 좋아 18.87% 상승했다. 회사 이사회는 15억 달러 규모의 새로운 자사주 매입 프로그램을 승인했고, 많은 분석가들은 <a href="https://www.benzinga.com/quote/team/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 예측</a>을 상향 조정했다.







<ol>
<li></li>
</ol>



Image via Shutterstock



Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Exelixis

뉴스

에 대한 최신 뉴스 Exelixis (NASDAQ:EXEL) 주식

일요일, 11월 03, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌